COVID-19 vaccines-The way forward
- PMID: 34191300
- PMCID: PMC8441906
- DOI: 10.1111/all.14995
COVID-19 vaccines-The way forward
Keywords: COVID; SARS-CoV; virus.
Conflict of interest statement
Dr. Klimek reports grants and/or personal fees from Allergopharma, MEDA/Mylan, HAL Allergie, ALK Abelló, LETI Pharma, Stallergenes, Quintiles, Sanofi, ASIT biotech, Lofarma, Allergy Therapeut., AstraZeneca, GSK, Inmunotk, Cassella med, outside the submitted work; and Membership: AeDA, DGHNO, Deutsche Akademie für Allergologie und klinische Immunologie, HNO‐BV, GPA, EAACI. Dr. Cooke reports to be a Member of the European Medicines Agency, Amsterdam, Netherlands. Dr. Jutel reports personal fees from ALK‐Abello, Allergopharma, Stallergenes, Anergis, Allergy Therapeutics, Leti, HAL, during the conduct of the study; personal fees from GSK, Novartis, Teva, Takeda, Chiesi, outside the submitted work. Dr. Akdis reports grants from Allergopharma, Idorsia, Swiss National Science Foundation, Christine Kühne‐Center for Allergy Research and Education, European Commission's Horison's 2020 Framework Programme, Cure, Novartis Research Institutes, Basel, Astra Zeneca, Switzerland, Scibase, Stockholm, advisory role for Sanofi/Regeneron, Glaxo Smith‐Kline, Novartis. Dr. Agache and Dr. O'Hehir have nothing to disclose.
References
-
- Eyes of the world are on medicines regulators . The race to produce COVID‐19 vaccines is a chance to create a more harmonized approvals process. Nature. 2020;588.
-
- COVID‐19 vaccines undergoing evaluation. 2021.
-
- Vaccine safety basics e‐learning course. 2021.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
